Form 4: Cytokinetics EVP Fady Ibraham Malik Reports Stock Transactions
SEC Form 4
Fady Ibraham Malik, EVP of Research & Development at Cytokinetics, reports the exercise of stock options and subsequent sale of shares on June 11, 2024.
Summary
- On June 11, 2024, Fady Ibraham Malik, EVP of Research & Development at Cytokinetics Inc., exercised non-qualified stock options to acquire 5,422 shares of common stock at a price of $7.96 per share.
- Simultaneously, Malik sold 5,422 shares at $53.05 and 2,366 shares at $53.03.
- Following these transactions, Malik directly owns 135,004 shares of Cytokinetics common stock.
- Malik also directly owns 68,900 non-qualified stock options.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of stock transactions. It doesn't inherently indicate positive or negative sentiment about the company's prospects.
Industry Context
This Form 4 filing is a routine disclosure of insider transactions, providing transparency to investors regarding the buying and selling activities of company executives. It's common for executives to exercise stock options and sell a portion of the acquired shares for personal financial management.
Stakeholder Impact
- The transactions may have a minor impact on shareholders due to the increased supply of shares in the market, but the effect is likely minimal given the relatively small number of shares involved.
Key Dates
| Date | Description |
|---|---|
| 03/26/2015 | Date the Non-Qualified Stock Option was granted. |
| 06/11/2024 | Date of the reported transactions: exercising options and selling shares. |
| 02/26/2025 | Expiration date of the Non-Qualified Stock Option. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.